CROSS-CLASS MATRIX
How Long It Lasts Decides What Can Be Known About It
BPC-157, CJC-1295, semaglutide, thymosin alpha-1 and PT-141 set side by side on the durability axis — and then followed through to what each choice did to the evidence base and the adverse-effect profile.
Abstract, in plain English
Comparing five peptides that do five unrelated things is usually a waste of a page. Lining up a gut hormone, a growth-hormone trigger, a tissue-repair fragment, an immune modulator and a desire drug tells a reader almost nothing about any of them.
So this page compares them on the one thing they genuinely have in common: how each was made to survive long enough to be studied at all. Two of them were chemically rebuilt and tied to a blood protein, and last for days. One was closed into a ring and lasts a few hours. Two were left as nature made them and last minutes.
Then the page follows that single number through its consequences. How long a compound lasts decides how often it must be given. How often it must be given decides what kind of study can realistically be run. What kind of study can be run decides what evidence exists — and, in the end, whether the compound ever became a medicine. It also decides when the side effects arrive and how long they stay.
Matrix one: what was done to each molecule
Each compound is placed here by what was done to it, and by what the published pharmacokinetics say resulted.
| Compound | Pharmacological class | Durability strategy | Published duration |
|---|---|---|---|
| BPC-157 | Cytoprotective gastric pentadecapeptide | None. Native fragment, chemically unaltered | Very short elimination half-life; modest intramuscular bioavailability; rapid breakdown to fragments [3] |
| CJC-1295 | GHRH analogue | Four DPP-IV-blocking substitutions plus covalent conjugation to albumin Cys34 [12] | Estimated half-life 5.8 to 8.1 days; IGF-1 raised for 9 to 11 days after a single dose [9] |
| Semaglutide | GLP-1 receptor agonist | Aib-8 substitution plus a C18 fatty di-acid binding albumin reversibly | Once-weekly subcutaneous dosing throughout the registrational programme [15][16] |
| Thymosin alpha-1 | Thymic immunomodulator | None. Sequence-identical to the endogenous 28-residue peptide | Short courses: a single dose, or repeated dosing over five to seven days [19] |
| PT-141 | Melanocortin MC3R/MC4R agonist | Cyclic lactam bridge closing an alpha-MSH fragment into a ring | Terminal half-life about 2.7 hours, range 1.9 to 4.0 hours [27] |
The spread across that last column is roughly three orders of magnitude, and it is not correlated with class, with tissue, or with how much anyone wanted the compound to work.
The four answers, and the trade each one made
Re-spelling the backbone is the cheapest intervention and the most transferable. CJC-1295 carries four substitutions that stabilise the alpha-helix and block dipeptidylpeptidase-IV cleavage, deamidation and oxidation. Semaglutide carries an alpha-aminoisobutyric acid at position 8 for the same enzymatic reason. In both cases the change is a handful of residues and the payoff is that the fastest clearance route is closed. What it does not do is address the kidney, which is why neither compound stops at substitution.
Tethering to albumin is what actually buys days. The two implementations differ in a way that turns out to matter more than it first appears. CJC-1295 binds albumin covalently, through a maleimidopropionyl linker that reacts with the free thiol on cysteine 34, producing a conjugate that showed a four-fold increase in growth-hormone area under the curve over two hours against the unconjugated parent in rats and remained detectable in plasma beyond seventy-two hours [12]. Semaglutide binds albumin reversibly, through a lipid that associates and dissociates. The covalent bond gives longer carriage; the reversible one gives a pharmacology that can be titrated up and stopped. For an outpatient medicine dispensed at scale, the second property is worth more than the first.
Cyclisation raises enzymatic stability and receptor selectivity by removing free termini and locking conformation. PT-141 demonstrates both the benefit and the ceiling: the ring survives the proteases, and the molecule is then cleared renally anyway, at a terminal half-life of about 2.7 hours with 64.8 per cent renal excretion [27].
Leaving the molecule alone is a strategy in one case and a default in the other. Thymosin alpha-1 is deliberately identical to the peptide the thymus cleaves from prothymosin alpha, because supplying the endogenous molecule is the therapeutic idea; its essential N-terminal acetylation is the body's own modification. BPC-157 is unmodified because no sponsor ever redesigned it, and the first formal pharmacokinetic characterisation reports what that leaves: linear kinetics, a very short elimination half-life, modest intramuscular bioavailability, and rapid breakdown into fragments entering ordinary amino-acid metabolism [3].
Matrix two: what each choice made possible
The second matrix is the one that carries the argument. Read left to right, each row is a causal chain rather than a list of attributes.
| Compound | Dosing format studied | Study design it permitted | Largest human enrolment | Regulatory status |
|---|---|---|---|---|
| BPC-157 | Repeated dosing in rodents; a single intravenous pilot in humans [1] | Rodent tissue endpoints; effectively no human programme [2] | 2 healthy adults [1] | Approved nowhere; prohibited in sport at all times |
| CJC-1295 | One subcutaneous dose, then sampling across days and weeks [9] | Human pharmacology against hormone endpoints; no clinical outcome trial | 11 healthy young men [8] | Approved nowhere; development discontinued; prohibited under WADA S2 |
| Semaglutide | Once-weekly subcutaneous injection; once-daily oral tablet [15][16] | Multi-year randomised trials against clinical event endpoints | 17,604 adults [15] | Approved for several indications |
| Thymosin alpha-1 | Subcutaneous course of five to seven days [19] | Acute-care trials against 28-day mortality [18][22] | 1,106 adults [18] | Approved in more than 35 countries, not in the United States [19] |
| PT-141 | As-needed 1.75 mg subcutaneous, at most once in 24 hours and eight times a month [27] | Episodic-use trials against patient-reported desire and distress scales [25] | 1,267 women across two identical trials [25] | Approved in the United States for one narrow indication [27] |
The pattern is hard to unsee once noticed. A compound that must be injected several times a day does not get randomised against a cardiovascular endpoint in seventeen thousand people [15], because nobody can run that trial. A compound given as a five-day course gets tested in illnesses that resolve or kill within a month [18][22], because that is the only endpoint its format can reach. A compound cleared in hours gets tested episodically, against how someone felt, in the window the drug was active [25]. Nobody chose those endpoints on scientific grounds alone; the pharmacokinetics chose them first.
The side-effect calendar is written by the same number
The second consequence of duration is less often stated and just as consistent. What a compound does is set by its receptor. When the effects arrive and how long they persist is set by how long the compound stays.
Sustained agents produce sustained effects, wanted and unwanted alike. CJC-1295 keeps growth hormone and IGF-1 elevated for days after a single dose and above baseline for weeks after several [9], and the effect its user communities report most is not a transient sensation but persistent fluid retention, puffiness and carpal-tunnel-like tingling — anecdotal, not clinical evidence, but exactly what a multi-day elevation of a sodium-and-water-retaining hormone predicts. Semaglutide's week-long exposure means gastrointestinal effects cluster around each dose increase and persist through it; nausea affects roughly a third of patients and gastrointestinal intolerance is the leading cause of discontinuation in trials [17]. The same long half-life is why its label carries a multi-week washout before planned conception.
Short-lived agents produce episodic effects. PT-141's adverse profile over 52 weeks of as-needed use is nausea at 40.4 per cent, flushing at 20.6 per cent and headache at 12.0 per cent [26] — high frequencies, but effects that arrive within an hour and resolve within hours, together with a transient blood-pressure rise that returns to baseline the same day [27]. And the two unmodified peptides converge on the mildest calendar of all: for thymosin alpha-1 the main expected adverse effect is local injection-site irritation, redness or discomfort [19], and the most common community report is noticing nothing.
One caveat belongs here. Frequency and severity are not the same axis. PT-141's nausea is both common and a leading reason people stop [26]; thymosin alpha-1's injection-site sting is common and trivial. Duration predicts the shape of an adverse-effect profile, not its seriousness.
Where this comparison stops
A comparison is only as good as its stated limits, and this one has three.
It says nothing about what any compound does. The receptor is the whole of that story, and no two compounds here share one: VEGFR2 on endothelium [4], the GHRH receptor on pituitary somatotrophs, GLP-1 receptors across pancreas, brainstem and hypothalamus, TLR2 and TLR9 on dendritic cells, MC4R in hypothalamic and limbic circuits [24]. Duration is portable between these five. Mechanism is not, and a reader who leaves this page with a general belief about what peptides do has taken the wrong thing from it.
It says nothing about whether the evidence is good. Semaglutide's file contains multiple large positive outcome trials [14][15][16]. Thymosin alpha-1's most rigorous trial is null [18]. PT-141's effects are statistically significant and, on the published re-analyses, small [25]. BPC-157's human file is three pilot studies [2]. These are not five points on one scale; they are four different epistemic situations, and none of them is predicted by half-life.
And it says nothing about whether any of this is a good idea for any person. This desk reads literature. It does not practise medicine, sell anything, or recommend a dose to anyone, and two of the five compounds here are approved medicines that require a prescriber while two more are approved nowhere at all.